Last reviewed · How we verify

Basal Insulin Analog

Eli Lilly and Company · FDA-approved active Small molecule

Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells.

Basal insulin analogs mimic the body's natural background insulin secretion by binding to insulin receptors and promoting glucose uptake into cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameBasal Insulin Analog
SponsorEli Lilly and Company
Drug classBasal insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Basal insulin analogs are long-acting insulin formulations designed to provide steady, background insulin coverage throughout the day and night, mimicking the basal insulin secretion of a healthy pancreas. They bind to insulin receptors on muscle, fat, and liver cells, facilitating glucose uptake and storage while suppressing hepatic glucose production. This helps maintain stable blood glucose levels between meals and overnight in patients with diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: